PO.ET05.03 · 实验与分子治疗
Role of the Microenvironment in Therapeutic Response
- 7169 7169 乳腺肿瘤的纵向单细胞图谱揭示对芳香化酶抑制剂敏感和耐药的免疫及表观遗传机制 Longitudinal single-cell profiling of breast tumors reveals immune and epigenetic mechanisms of sensitivity and resistance to aromatase inhibitors Ilayda Altinönder, Villads Winton, Quy Khang Le, Marie Fongaard, Paal M. Bjornstad, Elin Edda Seland Agustsdottir, Stephanie Geisler, Kamilla Fjermeros, Manouchehr Seyedzadeh, Unn-Cathrin Buvarp, Marianne Lyngra, Arnoldo Frigessi, Diether Lambrechts, Vessela N. Kristensen, Anthony Mathelier, Victor Greiff, Jürgen Geisler, Xavier Tekpli
- 7170 7170 用capivasertib抑制AKT可对抗肿瘤微环境重塑并增强PTEN缺陷型前列腺癌的AR靶向治疗 AKT inhibition with capivasertib counteracts tumor microenvironment remodeling and enhances AR-targeted therapy in PTEN-deficient prostate cancer Marco A. De Velasco, Kazuko Sakai, Daiki Nakatsu, Mamoru Hashimoto, Saizo Fujimoto, Shingo Toyoda, Takafumi Minami, Kazuhiro Yoshimura, Simon T. Barry, Cath Eberlein, Claire Rooney, Kazuto Nishio, Hirotsugu Uemura, Kazutoshi Fujita
-
7171 · PDF E7386联合lenvatinib在人子宫内膜癌异种移植模型中的抗肿瘤和抗血管生成活性 Antitumor and antiangiogenic activities of E7386 in combination with lenvatinib in human endometrial carcinoma xenograft models Yusuke Adachi, Yudai Narita, Shogo Yamaguchi, Taro Semba
- 7172 7172 B7-H4-TOP1i ADC、PD-1/TIGIT双特异性抗体与PARP抑制的联合在同基因小鼠模型中协调血管生成抑制和干扰素程序激活 Combination of B7-H4-TOP1i ADC, PD-1/TIGIT bispecific antibody, and PARP inhibition orchestrates angiogenesis suppression and interferon-program activation in a syngeneic mouse model Octavio Morante-Palacios, Jon Chesebrough, Yoshimi Johnson, Raymond Rothstein, Varsha Shankarappa, Joseph Boland, Elizabeth Galery, Anna Dominika Staniszewska, Mark R. Albertella, Alex Cazes, Paul Chariou, Bilal Omar
-
7173 · PDF 成纤维细胞激活蛋白激活型前药AVA6000在胰腺癌和脂肪肉瘤模型中的机制研究 Mechanistic studies of fibroblast activation protein activated prodrug AVA6000 in pancreatic and liposarcoma models Lisa Pickard, Ekta Paranjape, Brian Cunningham, Udai Banerji
-
7174 · PDF 通过OMO-103抑制MYC恢复抗肿瘤免疫并改善KRAS突变型NSCLC的免疫治疗结局 Restoring antitumor immunity and improving immunotherapy outcomes in KRAS-mutant NSCLC through MYC inhibition by OMO-103 Íñigo González-Larreategui, Sílvia Casacuberta-Serra, Magda Arnal, Daniel Capitán-Leo, Sandra Martínez-Martín, Vera Adradas, Melina Peressini, Laura Vera, Lorena Sansegundo-Barbosa, Fabio Giuntini, Manuel Lillo-Valero, Manrique Valdés-Bango Martín, Erika Serrano del Pozo, Judit Grueso, Laia Foradada, Sergio López-Estévez, Hugo Thabussot, Jonathan R. Whitfield, Marie-Eve Beaulieu, Jon Zugazagoitia, Silvestre Vicent, Laura Soucek
-
7175 · PDF 靶向CAFs与肿瘤细胞的空间模式以实现精准的基质靶向放射性核素治疗 Targeting spatial patterns of CAFs and tumor cells for precision stroma-targeted radionuclide therapy Yuning Sun, Ye Yang, Guanyu Zhu, Jiangang Zhang, Xiaowei Fan, Jian Wang, Yang Liu, Shaoyan Liu, Yansong Lin, Xi-Yang Cui, Zhibo Liu, Ziren Kong
-
7176 · PDF 新一代人源血管化肿瘤模型揭示T-DXd的HER2非依赖性疗效和降低的血管毒性 Next-generation human vascularized tumor models reveal HER2-independent efficacy and reduced vascular toxicity of T-DXd Francesco Bonollo, Soheila Zeinali, Sabine Schneider, Christian Moser, Olivier Thierry Guenat
-
7178 · PDF 靶向调控血-肿瘤屏障增强胶质母细胞瘤模型中的药物递送和生存 Targeted modulation of the blood-tumor barrier enhances drug delivery and survival in glioblastoma models Philippa C. Vaughn-Beaucaire, William Hawkins, Jasmine S. Clark, Jorge Luis Jimenez Macias, Bin Wu